Wall Street brokerages expect Epizyme Inc (NASDAQ:EPZM) to report sales of $2.83 million for the current quarter, Zacks reports. Three analysts have made estimates for Epizyme’s earnings, with the highest sales estimate coming in at $5.00 million and the lowest estimate coming in at $500,000.00. Epizyme reported sales of $9.70 million in the same quarter last year, which indicates a negative year over year growth rate of 70.8%. The company is scheduled to announce its next earnings results on Tuesday, February 25th.
According to Zacks, analysts expect that Epizyme will report full-year sales of $21.20 million for the current fiscal year, with estimates ranging from $19.51 million to $24.50 million. For the next fiscal year, analysts expect that the company will report sales of $34.53 million, with estimates ranging from $5.18 million to $63.60 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Epizyme.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.11. The company had revenue of $5.72 million during the quarter, compared to analysts’ expectations of $5.50 million. Epizyme had a negative net margin of 468.53% and a negative return on equity of 49.38%.
Several research analysts have issued reports on EPZM shares. BidaskClub lowered shares of Epizyme from a “buy” rating to a “hold” rating in a report on Wednesday. Zacks Investment Research cut shares of Epizyme from a “hold” rating to a “sell” rating and set a $11.00 target price for the company. in a research report on Monday, October 21st. Cowen reaffirmed a “buy” rating and issued a $18.00 price target on shares of Epizyme in a report on Thursday, October 31st. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research report on Thursday, October 31st. Finally, ValuEngine cut shares of Epizyme from a “hold” rating to a “sell” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $17.50.
A number of institutional investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Epizyme by 29.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,564 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 1,262 shares during the last quarter. Aperio Group LLC bought a new position in shares of Epizyme in the 2nd quarter worth $72,000. Rockefeller Capital Management L.P. purchased a new position in Epizyme in the second quarter worth $88,000. United Services Automobile Association acquired a new position in shares of Epizyme during the second quarter worth $134,000. Finally, HarbourVest Partners LLC purchased a new stake in shares of Epizyme during the 2nd quarter valued at $177,000. Institutional investors own 86.94% of the company’s stock.
Shares of NASDAQ:EPZM traded down $0.33 during trading on Friday, reaching $15.57. 17,312 shares of the stock were exchanged, compared to its average volume of 681,592. The firm’s 50-day moving average price is $13.63 and its 200 day moving average price is $12.84. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -9.06 and a beta of 2.58. Epizyme has a 12-month low of $5.14 and a 12-month high of $17.00. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.90 and a current ratio of 10.90.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Read More: What Are Treasury Bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.